Panzytrat

Selected form

Pancreatin

Method of action: Amylolytic, Enzymes, Lipolytic, Proteolytic, Replenishing Deficiency Of Pancreatic Enzymes

Treatment option: Cystic Fibrosis, Pancreatitis, Surgery, Chronic Pancreatitis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Panzytrat

Property	Description
Active Ingredient	Pancreatin (Pancrelipase)
Form	Oral, delayed-release capsule with enteric-coated microtablets
Pharmacological Class	Pancreatic Enzyme Replacement Therapy (PERT)
General Purpose	Supports and restores the digestion of macronutrients
Origin	Biologic, Porcine-derived (Animal source)

What Type of Medicine is Panzytrat?

Panzytrat is fundamentally a prescription medicine categorized as a Pancreatic Enzyme Replacement Therapy (PERT), which functions as a digestive enzyme supplement. Its high-level pharmacological classification is a pancreatic enzyme preparation or digestant, terms used to describe products that aid in the chemical processing of food within the body. This therapy is clinically recognized for its role in managing conditions characterized by insufficient natural enzyme production. The overall purpose of this therapy is to address an established deficiency in the body’s own production of these necessary digestive proteins, helping to stabilize the initial stages of the digestive process.

Pancreatin: Composition, Source, and Unique Form

The active pharmaceutical ingredient is Pancreatin, a concentrated mix of enzymes often referred to by its functional name, Pancrelipase. This protein-based concentrate contains the three primary digestive enzymes—lipase, amylase, and protease—and is derived from porcine pancreatic tissue (animal source). This specific porcine sourcing is utilized because of the close homology between animal and human pancreatic enzymes. Panzytrat is presented for oral administration as a delayed-release capsule that contains specialized enteric-coated microtablets. This coating is a critical design feature ensuring the active enzymes are protected from the degrading effects of gastric acid and are successfully released into the small intestine, which is the necessary site of their action.

The General Purpose of This Enzyme Replacement

The function of Panzytrat is local and substitutive, relying on the mechanism of hydrolysis to break down large food molecules. The enzymes perform their catalytic role by cleaving fats, starches, and proteins into smaller components that the body can readily absorb. A typical use scenario involves normalizing the digestive process after a meal, particularly for individuals who find it difficult to fully break down macronutrients. The general benefit is the restoration of efficient digestion, allowing the body to properly utilize the nutritional content of consumed food.

What side effects are possible with Panzytrat?

Possible side effects and safety information

The safety profile of Panzytrat, a Pancreatic Enzyme Replacement Therapy (PERT), is officially classified based on the frequency and affected organ system as detailed in regulatory documents from bodies like the FDA and EMA. The majority of documented adverse reactions are categorized as common and affect the gastrointestinal system.

Frequency-Classified Adverse Reactions

The most frequently reported effects, listed as common (occurring in ge 1/100 to <1/10 patients), involve the stomach and intestines. These include abdominal pain, flatulence, abdominal distension, diarrhea, vomiting, and constipation. Other common effects include headache, cough, and nasopharyngitis.

Serious Adverse Reactions and Safety Constraints

Official labeling highlights the existence of rare, but serious, adverse reactions. The most notable is fibrosing colonopathy, a severe bowel disorder that has been primarily reported in pediatric patients with cystic fibrosis who have received high dosages over prolonged periods. Pancreatin products are porcine-derived, which presents a safety consideration for individuals with porcine protein allergies, potentially leading to severe hypersensitivity reactions (including anaphylaxis), which have been reported with a frequency not known.

Safety Considerations

The product's high purine content is a safety consideration for individuals with a history of gout or hyperuricemia (high uric acid levels), as it may increase blood uric acid. Furthermore, the enzymes, if released prematurely, can irritate tissues; therefore, official safety statements note that chewing or crushing the enteric-coated microtablets may cause oral mucosal irritation.

Overdose and Emergency Response

The official regulatory documentation for Panzytrat (Pancrelipase) defines overdose primarily through acute physiological and metabolic manifestations. Overexposure to the high concentration of digestive enzymes can result in significant gastrointestinal discomfort. More specific findings documented in regulatory labels include elevated levels of uric acid in the blood and urine, known as hyperuricemia and hyperuricosuria. These metabolic changes are a consequence of the enzyme concentrate's high purine content.

A severe outcome, fibrosing colonopathy—a rare, serious condition involving scarring of the large intestine—has been associated with chronic, high-dose use of pancreatic enzyme products. This risk is specifically noted by regulatory authorities for pediatric patients with cystic fibrosis.

Official labeling provides strict instructions on emergency response. If an overdose is suspected, seek medical care right away or contact a poison control center. Immediate medical help is required if the affected person shows signs of acute compromise, such as seizure, collapse, or difficulty breathing. Management is primarily symptomatic and supportive, centered on discontinuing the medicine and monitoring key parameters, including blood uric acid levels. No specific antidote is explicitly known.

Therapeutic Uses of Panzytrat

What Panzytrat Treats: Main Uses and Benefits

Panzytrat is applied across domains where additional symptomatic support is needed, commonly known as Exocrine Pancreatic Insufficiency (EPI). It is commonly used when short-term symptomatic assistance is needed and provides support that helps ease the overall symptom burden linked to organ-specific functional stress. The therapy is considered relevant for symptomatic management in conditions such as chronic pancreatitis, cystic fibrosis, or following pancreatectomy.

Easing Digestive Discomfort and Bowel Manifestations

This treatment is applied in addressing symptoms related to physical discomfort that often arise following meals. Panzytrat assists in managing symptom clusters that may become intense or disruptive, such as abdominal fullness, bloating, and discomfort. It contributes to easing the overall symptom load during periods of heightened symptoms and is also relevant for managing symptoms that interfere with daily comfort, such as pronounced bowel manifestations like steatorrhea (fatty stools) and excessive gas.

“Panzytrat is applied across domains where additional symptomatic support is needed, helping to maintain a sense of stability when symptoms are more noticeable.”

It is commonly used across conditions presenting with acute episodes of Exocrine Pancreatic Insufficiency, such as Chronic Pancreatitis and Cystic Fibrosis. Relevant when supportive symptom management is appropriate, Panzytrat is applied in contexts involving heightened systemic burden. It assists with maintaining functional stability and supports the patient during difficult episodes by easing distress caused by the underlying disease.

Quick Fact
Support for Symptoms that Interfere with Comfort

Eligibility and Restrictions for Use

Panzytrat (Pancrelipase) eligibility is determined by specific contraindications, age guidelines, and caution rules documented in regulatory sources like the FDA and EMA.

Contraindications and Prohibited Use

Category	Regulatory Status
Porcine Protein Allergy	Contraindicated (Must not use due to hypersensitivity to the pig protein source or excipients).
Acute Pancreatitis	Not Recommended (Prohibited in some regional product labels).

Age and Conditional Use Rules

Panzytrat is approved for use in all ages, including infants (from birth), children, and adults with Exocrine Pancreatic Insufficiency.

However, specific populations require caution:

Population/Condition	Eligibility Constraint
Cystic Fibrosis Patients (High Dose)	Restricted Use/Caution. Doses above 2,500 lipase units/kg/meal mandate careful monitoring due to the labeled risk of fibrosing colonopathy.
Gout, Hyperuricemia, Renal Impairment	Caution Required. Patients with these conditions must use the medicine with caution due to the potential for increased blood uric acid levels.
Pregnancy and Lactation	Conditional Use. Use during pregnancy is generally considered low risk due to minimal systemic absorption; use during breastfeeding is acceptable with no anticipated effects on the infant.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Documented Interaction Patterns

The interaction profile of Panzytrat is defined by its enzymatic activity primarily within the gastrointestinal tract, leading to interactions classified as pharmacodynamic antagonism and reduced absorption rather than systemic metabolic (CYP450 enzyme) effects.

Category	Official Interaction Statement
Pharmacodynamic Antagonism	Co-administration with Alpha-Glucosidase Inhibitors (e.g., Acarbose, Miglitol) may reduce the therapeutic effect of these agents via enzymatic breakdown.
Reduced Exposure / Absorption	Co-administration may decrease the intestinal absorption and subsequent blood levels of Folic Acid and Oral Iron Salts (e.g., multivitamin products containing iron).
Intraluminal Interference	Certain Antacids (e.g., those containing calcium carbonate or magnesium hydroxide) may potentially reduce the beneficial enzymatic effect of the medicine.

Regulatory Constraints and Timing

The medicine is contraindicated for use in patients with known hypersensitivity to the active substance or to porcine protein, which is the source material for the enzyme concentrate. To mitigate the risk of reduced exposure for micronutrients, the administration of Panzytrat must be separated in time from the dosing of Oral Iron Salts and Folic Acid supplements, a procedural constraint defined in regulatory documents. No population-specific interaction considerations (e.g., heightened severity in hepatic impairment) are formally documented.

Mechanism of Action

How Panzytrat Works

Panzytrat introduces exogenous digestive enzymes into the gastrointestinal (GI) tract, where the mechanism of action is confined entirely to the GI lumen. It is an oral enzyme preparation composed of lipase, amylase, and protease that functions through direct catalytic interaction with dietary macromolecules.

Enzyme-Mediated Fat Hydrolysis

This domain centers on lipase interaction, which catalyzes the breakdown of ingested triglycerides into monoglycerides and fatty acids in the small intestine. The reaction yields these specific breakdown products and modulates the chemical composition of the luminal contents.

Facilitation of Starch and Protein Degradation

The mechanism also employs amylase and protease components. Amylase acts to degrade complex dietary starches (carbohydrates) into oligosaccharides, while protease acts to break down proteins into peptides and amino acids. This biochemical process contributes to the comprehensive degradation of food substrates prior to uptake.

Dosage and Administration Information

Administration of Panzytrat

Panzytrat capsules are intended for oral use. The capsules should be swallowed whole with a sufficient amount of liquid, such as a glass of water or fruit juice, during or immediately after meals or snacks.

For patients who have difficulty swallowing the entire capsule, such as young children or elderly individuals, the capsules can be carefully opened. The contained micro-tablets can then be added to small amounts of soft, acidic food that does not require chewing, such as applesauce or yogurt. Alternatively, the micro-tablets can be mixed with an acidic liquid like orange or pineapple juice.

Important Considerations for Use

Integrity of Micro-tablets: It is important that the micro-tablets are not crushed or chewed. The micro-tablets are coated with a special layer to protect the enzymes from stomach acid and to prevent irritation of the mouth and throat.
Immediate Consumption: If the micro-tablets are mixed with food or liquid, the mixture should be consumed immediately. It should not be stored for later use.
Hydration: Maintaining adequate fluid intake throughout the day is important when taking pancreatic enzyme replacement therapy.

Duration of Use

The duration of use is determined by the underlying condition and is generally intended for long-term therapy. The management of the condition and the continued need for the medication are typically monitored by a healthcare professional through regular assessments.

Recent Clinical Evidence

Panzytrat: Recent Clinical Evidence

This section provides a factual summary of the clinical research conducted for Panzytrat’s active ingredient, Pancrelipase. It outlines what researchers have studied, what findings were reported, and where certainty remains low, without offering any clinical guidance or recommendations.

Evidence for Use in Exocrine Pancreatic Insufficiency (EPI) due to Cystic Fibrosis

Research examined the formulation in patients with Cystic Fibrosis (CF) who have Exocrine Pancreatic Insufficiency (EPI). Research in this area is based on short-term, placebo-controlled Randomized Controlled Trials (RCTs). The outcomes monitored included functional biomarkers of digestion, such as the Coefficient of Fat Absorption (CFA), and patient-reported outcomes describing perceived discomfort. Studies reported measurements of CFA that described observed patterns related to the functional biomarker when comparing the active therapy to the inactive control in the short-term setting. Findings reflected the specific conditions under which they were conducted, typically over 5 to 14 days.

Evidence for Use in Exocrine Pancreatic Insufficiency (EPI) in Chronic Pancreatitis

The research examining this therapy in Chronic Pancreatitis involved a mix of RCTs and observational studies. These studies evaluated the formulation in adults with CP, a condition characterized by fluctuating or episodic manifestations. Studies monitored digestive biomarkers and outcomes related to systemic or functional imbalance, such as abdominal pain and bloating. Short-term trials reported measurements of CFA that data show patterns related to digestive function in the observed populations. However, findings were mixed across studies concerning the assessment of pain, reflecting the high heterogeneity in patient populations.

Understanding Research Gaps and Uncertainty

Long-term effects are not fully established; the existing research provides limited information for long-term outcomes across the entire evidence landscape for Pancrelipase. Furthermore, comparative evidence is lacking for different specific enzyme formulations, making it difficult to draw conclusions about one brand versus another. Evidence highlights what is known—and what is still uncertain—and research is ongoing to address these gaps.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Panzytrat (FAQ)

Q: What happens if I miss a dose of Panzytrat?

A: If a dose is missed, official regulatory guidance advises the patient to skip that dose completely. The recommended practice is to resume taking the product with the next scheduled meal or snack. This approach is designed to allow the enzyme replacement to synchronize with the food entering the digestive tract.

Q: How long will I have to take Panzytrat?

A: According to official product information, treatment with this medicine is generally described as a long-term maintenance therapy for chronic conditions. Specific duration of therapy is a clinical decision based on a patient's medical condition.

Q: What should I do with expired or unused Panzytrat?

A: To dispose of this medicine safely, regulatory documents state that it must not be thrown into household trash or poured down a drain. Official labeling advises consulting a pharmacist for instructions on how to properly discard any remaining capsules. This procedural guidance is intended to facilitate safe disposal and environmental protection.

Q: What is the maximum dose I can take per day?

A: Official dosing guidelines provide an explicit maximum limit per meal. A patient's total dose is generally not to exceed 2,500 lipase units per kilogram of body weight per meal. The product information does not specify a separate maximum daily total dose, as dosing is highly individualized based on diet.

Q: How should I store the medicine once the bottle is opened?

A: Once the bottle is initially opened, regulatory information states that the capsules must be used within six months. To maintain stability, the bottle is required to be kept in its original container and tightly closed. Proper storage is essential to protect the active enzymes from moisture and help maintain their intended effectiveness.

Q: What is the difference between Pancreatin, Pancrelipase, and Panzytrat?

A: The active substance in the medicine is Pancreatin, which is also referred to by its functional name, Pancrelipase. Pancrelipase is the specific mix of digestive enzymes (lipase, amylase, and protease). Panzytrat is the specific brand name given to this medicine by the manufacturer.

Q: What happens if the enzymes are damaged or not stored correctly?

A: The medicine is required to be kept in a dry place at a temperature below 25 C (77 F) to maintain the stability of the enzymes. Improper storage may result in damage to the enzymes. If the product's stability is compromised, its ability to aid in the digestion of food may be reduced.

How should Panzytrat be stored and disposed of?

How to Store and Dispose of Panzytrat?

Official labeling requires that Panzytrat capsules be stored under specific environmental constraints to maintain enzyme stability. The medicine must be kept in a dry place at a temperature that remains below 25 C (77 F).

Storage Requirements

Constraint	Requirement as per Official Labeling
Container	Must be kept in the original container and be tightly closed to protect from moisture.
Prohibited Areas	Do not store in damp places like bathrooms or near a sink. Avoid excessive heat.
Stability Period	Do not use past the expiry date. Capsules must be used within six months after the initial bottle opening.
Child Safety	Keep the medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Panzytrat must be disposed of according to strict guidelines. The product must not be thrown into household refuse or the sewage system. Consult a pharmacist for instructions on how to properly discard any remaining capsules.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.